THOR, ARQL, TIF, and AMTD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
December 28, 2019 14:00 ET
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Dec. 28, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: Synthorx, Inc. (NASDAQ GS: THOR) regarding possible breaches of fiduciary duties...
ArQule To Report Second Quarter 2016 Financial Results On August 3, 2016
July 20, 2016 07:00 ET
|
ArQule, Inc.
BURLINGTON, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the second quarter 2016 before the market opens on Wednesday,...
ArQule to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 12, 2016
July 05, 2016 07:00 ET
|
ArQule, Inc.
BURLINGTON, Mass., July 05, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of...
ArQule Reports First Quarter 2016 Financial Results
May 04, 2016 07:00 ET
|
ArQule, Inc.
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced its financial results for the first quarter of...
ArQule To Report First Quarter 2016 Financial Results On May 4, 2016
April 20, 2016 07:30 ET
|
ArQule, Inc.
BURLINGTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the first quarter 2016 before the market opens on Wednesday, May...
ArQule to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016
April 05, 2016 07:30 ET
|
ArQule, Inc.
BURLINGTON, Mass., April 05, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of...
ArQule Announces $15.3 Million Registered Direct Offering of Common Stock
February 29, 2016 06:55 ET
|
ArQule, Inc.
BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it has entered into definitive agreements with certain institutional and accredited investors to raise...
ArQule to Report Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
February 15, 2016 07:30 ET
|
ArQule, Inc.
BURLINGTON, Mass., Feb. 15, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it will report financial results for the fourth quarter and full year 2015 before the market opens on...
ArQule to Present at Upcoming Investor Conferences
February 04, 2016 07:30 ET
|
ArQule, Inc.
BURLINGTON, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer and Dr. Brian Schwartz, Chief Medical Officer and Head of...
ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 087
December 15, 2015 07:30 ET
|
ArQule, Inc.
Orphan drug designation marks significant regulatory milestone for phase 2 trialAdditional response in phase 1b further validates development for ARQ 087 in cancers with FGFR2 genetic alterations ...